! 7-(Diethylamino)-N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-2-oxo-2H-chromene-3carboxamide (2) . An oven-dried vial was charge with aniline 1 (50 mg, 0.097 mmol), 7diethylaminocoumarin-3-carboxylic acid (21 mg, 0.080 mmol) and anhydrous DMF (0.50 mL). HOBT (14 mg, 0.10 mmol) and DMAP (12 mg, 0.098 mmol) were added, the solution was cooled to 0 ºC, and EDCI (17 mg, 0.089 mmol) was added. The solution was stirred at rt overnight, warming to rt as it stirred. Water was added, and the yellow precipitate was collected by filtration and purified by chromatography (Biotage 12 g C18 cartridge; linear gradient of 10−70% MeCN/H2O with eluents containing 0.1% formic acid) to afford 2 (3.3 mg, 5%) as a yellow solid: 1 
!
Synthesis of analogs bearing a 7-hydroxycoumarin functionality. Acids with 7hydroxycoumarin (i.e., 7-hydroxy-2H-chromen-2-one) functionalities were protected as the corresponding acetates prior to use in amide bond forming reactions with aniline 1. The acetylation reactions were carried out using a reported protocol. 3 A representative procedure is as follows: A suspension of 7-hydroxycoumarin-3-carboxylic acid (20 mg, 0.097 mmol) in Ac2O (0.40 mL) was treated with BF3•OEt2 (4 drops) and shaken until homogeneity was observed (1 min) and then shaken for an additional 10 min. The solution was diluted with water (3 mL), shaken, and diluted with CH2Cl2 (5 mL). The organic layer was washed with brine, and concentrated in vacuo. After coevaporation with toluene and drying under vacuum overnight, the corresponding acetate (17 mg, 70%, crude) was obtained as an off-white solid. Acids were coevaporated with toluene immediately prior to subjection to reactions with aniline 1.
! N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2Htetrazol-5-yl)-4,5-dimethoxyphenyl)-7-hydroxy-2-oxo-2H-chromene-3-carboxamide (4).
An oven-dried microwave vial was charged with aniline 1 (20 mg, 0.039 mmol), 7acetoxycoumarin-3-carboxylic acid (8.1 mg, 0.033 mmol), DMAP (5.0 mg, 0.041 mmol), and anhydrous DMF (0.40 mL). The solution was cooled to 0 ºC, and HOBT (6.0 mg, 0.044 mmol) and EDCI (7.0 mg, 0.037 mmol) were added. The solution was stirred overnight, warming to rt as it stirred. The solution was diluted with CH2Cl2, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo. Purification by chromatography (Biotage 12 g C18 cartridge; linear gradient of 10−70% MeCN/H2O with eluents containing 0.1% formic acid ) afforded 4 (2.1 mg, 9%) as a yellow solid: 1 It should be noted that a mixture of acetylated and deacetylated products were observed in the crude mixture (LCMS analysis); the deacetylation likely occurs from the use of HOBT in the reaction protocol. In subsequent preparations of the material, the acetyl group stayed intact (i.e., when HOBT was not used as part of the protocol). It is feasible that the acetyl group could be removed using mild saponification conditions. Figure S3 . 1 
6-Chloro-N -(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-7-hydroxy-2-oxo-2H-chromene-3carboxamide (6).
A solution of aniline 1 (21 mg, 0.041 mmol), 6-chloro-7-acetoxycoumarin-3carboxylic acid (9.6 mg, 0.034 mmol), DMAP (5.0 mg, 0.041 mmol), and EDCI (7.1 mg, 0.037 mmol) in anhydrous DMF (0.40 mL) was stirred vigorously at rt overnight. The mixture was diluted with CH2Cl2, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo. Purification by chromatography (Biotage 12 g C18 cartridge; 10−80% MeCN/H2O) afforded 6 (6.4 mg, 25%) as a yellow solid: 1 
!
It should be noted that a mixture of acetylated and deacetylated products were observed in the crude mixture (LCMS analysis); in this case, the procedure reflects isolation of the deacetylated derivative. Figure S4 . 1 
7-(3-((2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2Htetrazol-5-yl)-4,5-dimethoxyphenyl)amino)-3-oxopropyl)-5,5-difluoro-1,3-dimethyl-5Hdipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (7)
. A solution of aniline 1 (3.5 mg, 0.0068 mmol) and BODIPY® FL (2.0 mg, 0.0068 mmol) in CH2Cl2 (0.10 mL) was treated with Et3N (5.0 µL, 0.036 mmol) and T3P (50% w/w in EtOAc, 7.0 µL, 0.010 mmol). The solution was flushed with argon and stirred at rt for 24 h. The solution was diluted with CH2Cl2 and washed with saturated aqueous NH4Cl, saturated aqueous NaHCO3, water, and brine, dried (Na2SO4), filtered, and concentrated in vacuo. Purification by chromatography (Biotage 12 g C18 cartridge; 30−100% MeCN/H2O with eluents containing 0.1% formic acid) afforded 7 (0.89 mg, 17%) as a red film: 1 
-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amino)ethyl)carbamate (S1).
A solution of aniline 1 (40 mg, 0.077 mmol) and N-Boc-2-aminoacetaldehyde (12 mg, 0.075 mmol) in CH2Cl2 was treated with NaHB(OAc)3 (25 mg, 0.12 mmol) and stirred at rt overnight. The mixture was diluted with CH2Cl2 and washed with saturated aqueous NaHCO3, water, and brine, dried (MgSO4), filtered, and concentrated in vacuo. Purification by chromatography on SiO2 (100% CH2Cl2, then 5% MeOH/CH2Cl2) afforded S1 (31 mg, 60%) as a yellow foam: Rf 0.25 (5% MeOH/CH2Cl2); 1 
Scheme S1. Synthesis of compound 8 via reductive amination of aniline 1.
! Figure S6 . 1 
-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2Htetrazol-5-yl)-4,5-dimethoxyphenyl)ethane-1,2-diamine (S2).
A solution of S1 (12.5 mg, 0.0190 mmol) in CH2Cl2 (0.40 mL) was treated with 10% TFA in CH2Cl2 (0.40 mL) and stirred at rt overnight. The solution was diluted with CH2Cl2 and washed with saturated NaHCO3, water, and brine, dried (Na2SO4), and concentrated in vacuo to afford S2 (8.7 mg, 83% (crude)) as an amorphous yellow solid: 1 N-(2-((2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl) 
ethyl)phenyl)-2Htetrazol-5-yl)-4,5-dimethoxyphenyl)amino)ethyl)-6,8-difluoro-7-hydroxy-2-oxo-2Hchromene-3-carboxamide (8).
A solution of crude amine S2 (4.5 mg,0.0080 mmol) and Pacific Blue, SE (1.5 mg, 0.0044 mmol) in DMF (0.1 mL) was treated with DIPEA (3.0 µL, 0.017 mmol), and the solution was shaken at rt overnight. The solution was loaded directly onto a C18 12 g cartridge, and purification was accomplished by reverse-phase chromatography (Biotage, C18 12 g cartridge, 20−80% MeCN/H2O) to afford 8 as a yellow film. Residual DMF was present in the bulk sample, and aliquots were taken up in EtOAc and washed with water to remove DMF prior to cell-based assay. An analytical sample for 1 H NMR analysis was also obtained in this manner: 1 
! !
Quantum yield determinations. Quantum yields were measured following methods described in the literature. 4 The calculations were performed by comparing the area under the curve of the test compounds (diluted in PBS) to that of coumarin 153 in EtOH; relative quantum yields were calculated using a value of 0.58 for the quantum yield of coumarin-153 in EtOH. All measurements were performed by making dilutions of DMSO stock solutions in PBS to volumes of 5.0 mL; aliquots sufficient to fill a 1 cm cuvette (3.0 mL) were measured in 1 cm quartz cuvettes (Starna Cells, Inc., Atascadero, CA, catalog number 3-Q-10) using a Spectromax® M3 UV/VIS spectrophotometer (Molecular Devices, Sunnyvale, CA).

Cell lines and cell viability experiments
!
Cell lines. HT1080 Fibrosarcoma cells (ATCC) were maintained at 37 °C, 5% CO2 and 100% relative humidity in minimum essential medium supplemented with 10% fetal bovine serum, 100 IU penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, nonessential amino acids. A cell line expressing MDR1 fused to the Apple fluorescent protein was generated to screen MDR1++ clones and to induce paclitaxel resistance in a taxane-sensitive cell line, using the Lenti-X HTX Packaging System (Clontech, Catalog # 631247, Mountain View, CA). Cells were selected in 3 μg/mL puromycin, and clones were screened for MDR1-Apple expression by fluorescence microscopy.
The HT1080 and HT1080-MDR1-Apple cells were additionally labeled with a histone H2B-iRFP fusion protein for in vivo visualization of the nucleus, also using the Lenti-X HTX Packaging System (Clontech, Catalog # 631247, Mountain View, CA). The iRFP plasmid was a kind gift from Professor Vladislav Verkhusha at the Albert Einstein College of Medicine (Bronx, NY). Both inserts were sequenced in their entirety.
Western blot. Cell lysates were prepared by harvesting cells on ice in RIPA Buffer (Cell Signaling Technology, Catalog # 9806S, Danvers, MA) with protease inhibitors, while vigorously vortexing. Total protein concentration was measured using the Pierce BCA Protein Assay (Thermo Scientific, Catalog # 23225, Rockford, IL) and each lysate was diluted to 1 μg total protein in RIPA buffer and LDS sample buffer (Invitrogen, Grand Island, NY). Lysates were denatured for 10 min at 70 °C or 30 min at 4 °C, electrophoresed on a NuPage 4-12% Bis-Tris Gel (Invitrogen, Catalog # NP0323, Carlsbad, CA) and transferred to polyvinylidene fluoride (PVDF) membrane using the iBlot system (Invitrogen). Blots were blocked for 1 h in SuperBlock T20 (TBS) blocking buffer (Thermo Scientific) and briefly washed with TBS containing 0.1% Tween-20 (TBST). The blots were then incubated for 3 h at room temperature with a 1:500 dilution of anti-P-Glycoprotein-mouse (C219, EMD Millipore, Catalog #517310, Billerica, MA) or a 1:3000 dilution of anti-GAPDH-goat (R&D Systems, Minneapolis, MN) primary antibodies in TBST containing 10% SuperBlock. Blots were then washed three times in TBST, incubated for 1 h in species specific HRP-conjugated secondary antibodies (1:6000 and 1:1000 respectively), and washed an additional three times in TBST. SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Catalog #34077, Rockford, IL) was used to detect the MDR1 P-glycoprotein relative to GAPDH.
. Western blot showing the abundance of MDR1protein in HT1080-MDR1++ cells that overexpress the MDR1; the basal expression of MDR1 in wild-type HT1080 cells is low.
Cell viability. Cell viability assays were performed in 96-well format; cells were seeded at 2500 cells/well in 200 µL Dulbecco's Modified Eagle Medium 24 hours prior to application of the test compounds. Increasing concentrations of HM30181 analogs (100 nM to 5 µM) and paclitaxel (10 nM to 1 µM) were dissolved in DMSO and added to each well, while maintaining a final DMSO concentration of 0.1%. After incubating for 24 h, the media was replaced with media without drug/inhibitor, and the cells were incubated for an additional 48−72 h (allowing time for cell division). Cell viability was quantified using the PrestoBlue cell viability reagent (Life Technologies, catalog #A-13261, Grand Island, NY) and the TECAN Safire2 plate reader (Mannedorf, Switzerland). Fluorescence measurements were normalized to cells exposed to a DMSO control (no drug/inhibitor), and drug concentrations were log-transformed, and halfmaximal effective concentrations were estimated by nonlinear regression to a sigmoidal dose response using the Prism 6.0 Software Suite (GraphPad, La Jolla, CA). All measurements were preformed in triplicate and are presented as means +/-standard deviation. ! Inhibitory activity against breast cancer resistance protein (BCRP). Affinity for the efflux transporter BCRP, an alternative target for MDR1 substrates and inhibitors, is another target of interest. It has been reported that HM30181 shows relatively low modulatory activity toward BCRP. 5 We assessed the effect of adding a relatively high concentration (1 µM) of the companion imaging agent 4 to BCRP membrane vesicles activated with sulfasalazine. No appreciable inhibitory activity of 4 was observed at this concentration.
The experimental procedure was as follows: The activity of agent 4 and related inhibitors against a separate membrane transport protein, BCRP, were determined using the ATPase assay kit (BD Biosciences via Corning, catalog #459006) according to the manufacturer's instructions. Note that the final assay volume is 60 µL. Purified human BCRP membrane (Corning, catalog #452370) was diluted to 1 mg/mL; 20 µL aliquots were pre-incubated at 37 ºC for 5 min with solutions of sulfasalazine (activator, 10 µM final assay concentration) and the requisite inhibitor (1 µM final concentration, diluted from a DMSO stock solution) with or without aqueous sodium orthovanadate (solutions without sodium orthovanadate were diluted with the corresponding amount of deionized water). Control samples without inhibitor or sulfasalazine were normalized with the appropriate amount of DMSO. The samples were treated with Mg-ATP (20 µL, 4 mM final assay concentration) and incubated for 15 min at 37 ºC. The reaction was stopped by addition of SDS stop solution, and the amount of phosphate released was determined using the absorbance at 800 nm after addition and incubation with the commercial color indicator solution (incubated for 20 min at 37 ºC). The amount of phosphate released was quantified by comparison to a standard curve, and the reported values are corrected for the amount of phosphate released in samples treated with sodium orthovanadate. The experiments were performed in duplicate.
Cellular Imaging Experiments
!
Cellular imaging experiments to evaluate inhibitor co-localization. A mixed population of paclitaxel -sensitive (HT1080-H2B-iRFP) and paclitaxel refractory (HT1080-H2B-iRFP-MDR1-Apple) cell lines were imaged after a 1 h incubation with Compound 4 (3.2 µM, prepared by dilution of a 10 mM DMSO stock solution) in phenol-red free Dulbecco's Modified Eagle Medium. Cells were seeded in a 6-well format at 5000 cells/well 48h prior to imaging. All imaging experiments were performed using a customized Olympus FV1000 confocal laser scanning microscope (Olympus America) with a Olympus 20x XLUMPLanFLN (NA 1.0) or a 60x LUMFL N (NA.1.10) water immersion objective. Samples were excited sequentially with a 405 nm, a 473 nm, and a 663 nm diode laser and a 559 DPSS laser using a DM405/488/559/635 beam splitter. Emitted light was separated using beam splitters SDM473, SDM560 and SDM640 and band pass filters BA430-455, BA490-540, BA575-620 and BA655-755. Laser power in all channels was minimized to prevent photo damage to fluorescent compounds or cells.
Cellular imaging experiment to evaluate inhibitor function. A mixed population of paclitaxel sensitive (HT1080-H2B-iRFP) and paclitaxel refractory (HT1080-H2B-IRFP-MDR1-Apple) cell lines were imaged after a) 1 h incubation with 50 nM olaparib-BFL or b) 1 h incubation with 5 µM 4 and 50 nM olaparib-BFL in phenol-red free Dulbecco's Modified Eagle Medium. The media was exchanged for either a) phenol-red free media or b) phenol-red free media containing 5 µM 4 and imaged.
Competitive inhibition with unmodified HM30181. A mixed population of paclitaxel sensitive (HT1080-H2B-iRFP) and paclitaxel refractory (HT1080-H2B-iRFP-MDR1-Apple) cells were plated in a 6-well format 24 h prior to imaging. Cells were incubated for 2.5 h prior to imaging with a) phenol-red free Dulbecco's Modified Eagle Medium (control) or b) 30 µM HM30181 in phenol-red free Dulbecco's Modified Eagle Medium (prepared by dilution of a 10 mM stock solution of HM30181 in DMSO). A background image was acquired before washout; then the media was exchanged with phenol-red free Dulbecco's Modified Eagle Medium containing 3 µM compound 4 (prepared by dilution of a 10 mM stock solution of 4 in DMSO). Time-lapse microscopy was performed to quantify the accumulation dynamics of 4 until steady state was achieved (15 min) ( Figure S13 ). 
